ABOS News and Press, Acumen Pharmaceuticals Inc. From 11/15/21

Acumen Pharmaceuticals (NASDAQ:ABOS): Q3 GAAP EPS of -$0.10 beats by $0.07. Cash equivalents and marketable securities of $199.96M Press Release For further details see: Acumen Pharmaceuticals EPS beats by $0.07

Acumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trials Enrolled first patients in INTERCEPT-AD, a multi-center, rando...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company wi...

ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Acumen announced dosing of first patient in INTERCEPT-AD in October 2021 and enrollment of patients with ...

ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Enrollment of early Alzheimer’s patients is ongoing in INTERCEPT-AD, the Phase 1 placebo-controlled,...

Are These Top Biotech Stocks Worth Buying This Week? When considering which stocks to invest in amidst current stock market conditions, most would look towards the health care sector. Among biotech stocks, one subsection, in particular, continues to make headlines. That is t...

Gainers: ZIOPHARM Oncology (NASDAQ:ZIOP) +39%, RenovoRx (NASDAQ:RNXT) +17%, Sigilon Therapeutics (NASDAQ:SGTX) +17%, Acumen Pharmaceuticals (NASDAQ:ABOS) +15%, NeuroOne Medical Technologies (NASDAQ:NMTC) +7%. Losers: CorMedix (NASDAQ:CRMD) -25...

As September started, the healthcare stocks in the S&P 500 returned to post gains after a brief decline last week. Thanks mainly to health insurers, the S&P 500 Healthcare Sector Index posted the biggest one-day gain in more than two weeks on Thursday. Becoming the second-best pe...

Acumen Pharmaceuticals (NASDAQ:ABOS): Q2 EPS of -$141.93 may not be comparable to consensus of -$4.56. Cash Balance. Cash, cash equivalents and marketable securities were $68.8 million as of June 30, 2021, compared to $43.8 million as of December 31, 2020. Press Release For further details ...

Acumen’s investigational drug, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trials Initiated ACU-001, a multi-center, randomized, double-blind, placebo-contro...